In the mice without FcγR blockade, tumor growth inhibition was significantly greater for TG-VHS treatment than for the combination treatment, whereas in the mice with FcγR blockade, the difference between TG-VHS and the combination treatment was notably smaller and not statistically significant. The gene discussed is FCGR2A; the disease is neoplasm.